Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Halberd Corporation < Previous 1 2 Next > Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary July 20, 2022 From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers HALB Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron July 14, 2022 From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Tickers HALB Halberd Corporation Update, CEO Letter and 2022 Expectations July 12, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer June 21, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification June 08, 2022 From Halberd Corporation Via AccessWire Topics Animal Testing Exposures Animal Testing Product Safety Tickers HALB Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines May 24, 2022 From Halberd Corporation Via AccessWire Topics Animal Testing Exposures Animal Testing Product Safety Tickers HALB Halberd Engages Professional Firm to Proceed with FDA Filings May 18, 2022 From Halberd Corporation Via AccessWire Exposures Product Safety Tickers HALB Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB May 12, 2022 From Halberd Corporation Via AccessWire Topics Animal Testing Regulatory Compliance Exposures Animal Testing Legal Product Safety Tickers HALB Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases April 29, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd CEO Letter April 25, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics April 18, 2022 From Halberd Corporation Via AccessWire Topics Animal Testing Exposures Animal Testing Tickers HALB Halberd Entering the Medical Metaverse(TM) April 11, 2022 From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers HALB Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression April 04, 2022 From Halberd Corporation Via AccessWire Tickers HALB Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans March 16, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor March 08, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant March 01, 2022 From Halberd Corporation Via AccessWire Exposures COVID-19 Product Safety Tickers HALB Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually February 22, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens February 08, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture February 01, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd CEO Letter: 2021 Year-End & 2022 Outlook January 25, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases January 13, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Corporation Now an Official US Government Contractor January 05, 2022 From Halberd Corporation Via AccessWire Tickers HALB Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases December 20, 2021 From Halberd Corporation Via AccessWire Tickers HALB Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases December 15, 2021 From Halberd Corporation Via AccessWire Tickers HALB Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases December 13, 2021 From Halberd Corporation Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Tickers HALB Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE December 06, 2021 From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers HALB Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease November 22, 2021 From Halberd Corporation Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Tickers HALB Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves November 08, 2021 From Halberd Corporation Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Tickers HALB Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease November 01, 2021 From Halberd Corporation Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Tickers HALB Halberd Files Provisional Patent on Breakthrough Obesity Treatment October 25, 2021 From Halberd Corporation Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Tickers HALB < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.